التفاصيل البيبلوغرافية
| العنوان: |
Selenium-Containing (Hetero)Aryl Hybrids as Potential Antileishmanial Drug Candidates: In Vitro Screening against L. amazonensis. |
| المؤلفون: |
Fermiano, Maria Helena, das Neves, Amarith Rodrigues, da Silva, Fernanda, Barros, Manuella Salustiano Andrade, Vieira, Camila Barbosa, Stein, André L., Frizon, Tiago Elias Allievi, Braga, Antonio Luiz, de Arruda, Carla Cardozo Pinto, Parisotto, Eduardo Benedetti, Saba, Sumbal, Rafique, Jamal, Riul, Thalita Bachelli |
| المصدر: |
Biomedicines; Jan2024, Vol. 12 Issue 1, p213, 13p |
| مصطلحات موضوعية: |
PERITONEAL macrophages, SELENIUM compounds, CYTOTOXINS, LEISHMANIASIS, COUMARINS, AMASTIGOTES |
| الشركة/الكيان: |
NATIONAL Institutes of Health (U.S.) |
| مستخلص: |
Leishmaniasis remains a significant global health concern, with current treatments relying on outdated drugs associated with high toxicity, lengthy administration, elevated costs, and drug resistance. Consequently, the urgent need for safer and more effective therapeutic options in leishmaniasis treatment persists. Previous research has highlighted selenium compounds as promising candidates for innovative leishmaniasis therapy. In light of this, a library of 10 selenium-containing diverse compounds was designed and evaluated in this study. These compounds included selenium-substituted indole, coumarin, chromone, oxadiazole, imidazo[1,2-a]pyridine, Imidazo[2,1-b]thiazole, and oxazole, among others. These compounds were screened against Leishmania amazonensis promastigotes and intracellular amastigotes, and their cytotoxicity was assessed in peritoneal macrophages, NIH/3T3, and J774A.1 cells. Among the tested compounds, MRK-106 and MRK-108 displayed the highest potency against L. amazonensis promastigotes with reduced cytotoxicity. Notably, MRK-106 and MRK-108 exhibited IC50 values of 3.97 µM and 4.23 µM, respectively, and most of the tested compounds showed low cytotoxicity in host cells (CC50 > 200 µM). Also, compounds MRK-107 and MRK-113 showed activity against intracellular amastigotes (IC50 18.31 and 15.93 µM and SI 12.55 and 10.92, respectively). In conclusion, the identified selenium-containing compounds hold potential structures as antileishmanial drug candidates to be further explored in subsequent studies. These findings represent a significant step toward the development of safer and more effective therapies for leishmaniasis, addressing the pressing need for novel and improved treatments. [ABSTRACT FROM AUTHOR] |
|
Copyright of Biomedicines is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder